-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
Provectus starts Phase 1 trial for liver cancer treatment
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver cancer that will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma. The primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients Read More >
XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease
XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta (IL-1 beta), XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseases. The clinical trials are designed to further evaluate the use of multiple dose regimens on the safety, pharmacodynamics and efficacy of XOMA 052 in cardiometabolic and other diseases, and based on positive results, select doses for pivotal Read More >
U.S. Navy to fund Vical’s H1N1 vaccine
The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations, which are already underway, for a Phase 1 clinical trial of the company’s vaccine against A/H1N1 pandemic influenza. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center. Vical was the first company to produce a vaccine against the A/H1N1 influenza virus after the initial reports Read More >
Hana Biosciences’ clinical trial agreement with the National Cancer Institute
Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Read More >
Intarcia presents positive results of Type 2 Diabetes study
Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes, which demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period. Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.
